Citius Pharmaceuticals to Host Investor Call on Phase 3 Mino-Lok Trial Results

CRANFORD, N.J., May 29, 2024 -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a late-stage biopharmaceutical company focused on developing and commercializing innovative critical care products, will host an investor call on Monday, June 3, 2024 at 8:30 AM ET. The purpose of the call is to discuss the topline results from its Phase 3 Trial of Mino-Lok, an antibiotic lock solution designed to treat catheter-related bloodstream infections.

The discussion will be led by Citius Chairman and CEO, Leonard Mazur, alongside other key members of the management team. They will elaborate on the findings of the Phase 3 Trial and the clinical necessity for Mino-Lok in patients suffering from these severe infections. Following the management's presentation, there will be a question and answer session for investors.

Citius Pharmaceuticals is renowned for its development pipeline that includes two advanced-stage product candidates: Mino-Lok and LYMPHIR. Mino-Lok recently reported favorable topline results in May 2024. This antibiotic lock solution aims to salvage catheters in patients with bloodstream infections, providing an important treatment option in critical care settings.

Additionally, the company’s other key candidate, LYMPHIR, is currently under FDA review. LYMPHIR is a novel IL-2R immunotherapy designed to treat cutaneous T-cell lymphoma (CTCL). The FDA has set a target action date of August 13, 2024, for the Biologics License Application. LYMPHIR has been granted orphan drug designation by the FDA, recognizing its potential to treat both CTCL and peripheral T-cell lymphoma (PTCL).

Citius has also announced its intention to establish Citius Oncology, a standalone publicly traded entity, with LYMPHIR as its primary asset. This strategic move aims to focus on the oncology sector and leverage LYMPHIR’s potential in treating rare cancers.

Beyond these key developments, Citius has completed enrollment in its Phase 2b trial for CITI-002 (Halo-Lido), a topical medication intended to provide relief for hemorrhoids. This diversified pipeline underscores Citius’s commitment to addressing unmet medical needs in critical care and other therapeutic areas.

The upcoming investor call on June 3, 2024, is a significant event for stakeholders to gain insights into the latest clinical developments and the company’s strategic direction. Investors and interested parties are encouraged to join the call to hear the detailed analysis and future prospects directly from the company's leadership.

Citius Pharmaceuticals continues to push the boundaries in biopharmaceutical innovation, with a clear focus on developing first-in-class products that address significant medical needs. The positive results from the Mino-Lok Phase 3 Trial and the ongoing review of LYMPHIR by the FDA highlight the company's potential to make a substantial impact in the fields of critical care and oncology.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!